Skip to content

Study · Animal study (in vivo) · mouse · 2016

2 results

Hypothalamic POMC Deficiency Improves Glucose Tolerance Despite Insulin Resistance by Increasing Glycosuria.

Chhabra KH, Adams JM, Fagel B, Lam DD, Qi N, Rubinstein M, Low MJ

Diabetes14 Oct 2015Cited by 48 (Europe PMC)

PMID26467632 (opens in a new tab)PMCIDPMC4764146 (opens in a new tab)DOI10.2337/db15-0804 (opens in a new tab)PepBankPUB-26467632
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In ArcPOMC-deficient mice, central melanotan II reversed the improved glucose tolerance.

    In plain wordsIn mice lacking hypothalamic POMC, melanotan II given into the brain reversed their unusually good glucose tolerance.

    Peptide
    Melanotan II
    Outcome
    DecreaseGlucose tolerance in ArcPOMC-deficient mice
    Study

    mousen: not reported in source

    ArcPOMC-deficient mice
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · centralAs given in this study (mouse).

    Source sentences

    Summary
    Central administration of the melanocortin receptor agonist melanotan II in mutant mice reversed alterations in glucose tolerance and glycosuria
    1 context sentence
    Summary · context
    We show that hypothalamic arcuate nucleus (Arc)POMC-deficient mice, which develop severe obesity and insulin resistance, unexpectedly exhibit improved glucose tolerance and remain protected from hyperglycemia.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In ArcPOMC-deficient mice, central melanotan II reversed the exaggerated glycosuria.

    In plain wordsIn mice lacking hypothalamic POMC, melanotan II given into the brain reversed their raised sugar loss in urine.

    Peptide
    Melanotan II
    Outcome
    DecreaseGlycosuria in ArcPOMC-deficient mice
    Study

    mousen: not reported in source

    ArcPOMC-deficient mice
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    Dose not stated · centralAs given in this study (mouse).

    Source sentences

    Summary
    Central administration of the melanocortin receptor agonist melanotan II in mutant mice reversed alterations in glucose tolerance and glycosuria
    1 context sentence
    Summary · context
    We show that hypothalamic arcuate nucleus (Arc)POMC-deficient mice, which develop severe obesity and insulin resistance, unexpectedly exhibit improved glucose tolerance and remain protected from hyperglycemia.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.